Winthrop Pharmaceuticals UK Ltd

One Onslow Street, Guildford, Surrey, GU1 4YS, UK
Telephone: +44 (0)1483 505 515
Fax: +44 (0)1483 554 831
E-mail: UK-medicalinformation@sanofi-aventis.com
Medical Information Direct Line: +44 (0)1483 554 101
Medical Information Fax: +44 (0)1483 554 831
Summary of Product Characteristics last updated on the eMC: 05/01/2009
SPC Vallergan Forte Syrup

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 05/01/2009 and displayed until Current
Reasons for adding or updating:
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   13-Nov-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Change to presentation not marketed which resulted in change of data of variation
Updated on 21/02/2008 and displayed until 05/01/2009
Reasons for adding or updating:
  • Change to section 6.1 - List of Excipients
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   10/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 6.1
 
Demineralised water
 
changed to  
 
water, purified
Updated on 20/09/2007 and displayed until 21/02/2008
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   04/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 7 (Marketing Authorisation Holder): change to sanofi-aventis.
 
Section 8 (Marketing Authorisation Number): change to PL04425/0381
 
Section 9 (Date of First renewal/Renewal of Authorisation): 15 December 2006
 
Section 10 (Date of revision of text): 20 April 2007
 
Updated on 26/09/2006 and displayed until 20/09/2007
Reasons for adding or updating:
  • Addition of separate SPCs covering individual presentations
Date of revision of text on the SPC:   07/2005
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

No changes to the text of the SPC has been made. Previous SPC on the eMC included all three Vallergan presentations on the one . This SPC has been entered due to the addition of separate SPCs covering individual presentations within the range of Vallergan.

Active Ingredients/Generics

 
   alimemazine tartrate


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk